Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing

Journal of Clinical Microbiology

Volumn 35, Issue 3, 1997, Pages 631-635

  Lathey, Janet L ^a,d   Marschner, Ian C ^b   Kabat, Bill ^c   Spector, Stephen A ^a,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ANTIGEN DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN STABILITY; SAMPLING; SERUM; VIRUS DETECTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031057721     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.35.3.631-635.1997     Document Type: Article

References (18)

1. Aboulker, J. P., and A. M. Swart. 1993. Preliminary analysis of the Concorde trial. Lancet 341:889-890.
2. Altman, D. G. 1991. Practical statistics for medical research. Chapman & Hall, London, United Kingdom.
3. Bozzette, S. A., and D. D. Richman. 1990. Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. Am. J. Med. 88:24S-26S.
4. Brady, M. T., N. McGrath, P. Brouwers, G. Gelber, M. G. Fowler, R. Yogev, N. Hutton, Y. J. Bryson, C. D. Mitchell, S. Fikrig, W. Borkowsky, E. Jimenez, G. McSherry, A. Rubinstein, C. M. Wilfert, K. McIntosh, M. M. Elkins, P. S. Weintrub, and the Pediatric AIDS Clinical Trials Group. 1996. Randomized study of the tolerance and efficacy of high-versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). J. Infect. Dis. 173:1097-1106.
5. Cheeseman, S. H., D. Havlir, D. Hall, S. E. Hattox, S. A. Spector, D. S. Stein, M. Myers, and D. D. Richman. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 8:141-151.
6. DeGruttola, V., L. A. Beckett, R. W. Coombs, J. M. Arduino, H. H. Balfour, S. Rasheed, F. B. Hollinger, M. A. Fischl, P. Volberding, and AIDS Clinical Trials Group Virology Laboratories. 1994. Serum p24 antigen levels as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1 (HIV-1). J. Infect. Dis. 169:713-721.
7. Dobson, A. J. 1990. An introduction to generalized linear models. Chapman & Hall, London, United Kingdom.
8. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
9. Fiscus, S. A., V. DeGruttola, P. Gupta, D. A. Katzenstein, W. A. Meyer, M. L. LoFaro, M. Katzman, M. V. Ragni, P. S. Reichelderfer, and R. W. Coombs. 1995. Human immunodeficiency virus type-1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J. Infect. Dis. 17:305-311.
10. Griffith, B. P., H. Brett-Smith, G. Kim, J. W. Mellors, T. M. Chacko, R. B. Garner, Y. Cheng, P. Alcabes, and G. Friedland. 1996. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J. Infect. Dis. 173:1252-1255.
11. Griffith, B. P., R. B. Garner, and T. N. Chacko. 1995. Stability of free and complexed human immunodeficiency virus type 1 antigen at 4°C and at room temperature. J. Clin. Microbiol. 33:1348-1350.
12. Hammer, S., C. Crumpacker, R. D'Aquila, B. Jackson, J. Lathey, D. Livnat, and P. Reichelderfer. 1993. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group virology committee. J. Clin. Microbiol. 31:2557-2564.
13. Haubrich, R. H., C. Flexner, M. M. Lederman, M. Hirsch, C. P. Pettinelli, R. Ginsberg, P. Lietman, F. M. Hamzeh, S. A. Spector, D. D. Richman, and the AIDS Clinical Trials Group 213 Team. 1995. A randomized trial of the activity and safety of Ro 12-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. J. Infect. Dis. 172:1246-1252.
14. Kappes, J. C., M. S. Saag, M. Shaw, B. H. Hahn, P. Chopra, S. Chen, E. A. Emini, R. McFarland, L. C. Yang, M. Piatak, and J. D. Lifson. 1995. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared. J. Acquired Immune Defic. Syndr. 10:139-149.
15. Shepp, D. H., and A. Ashraf. 1993. Effect of didanosine on human immunodeficiency virus viremia and antigenemia in patients with advanced disease: correlation with clinical response. J. Infect. Dis. 167:30-35.
16. Skowron, G., S. A. Bozzette, L. Lim, C. B. Pettinelli, H. H. Schaumburg, J. Arezzo, M. A. Fischl, W. G. Powderly, D. G. Gocke, D. D. Richman, J. C. Pottage, D. Antoniskis, G. F. McKinley, N. E. Hyslop, G. Ray, G. Simon, N. Reed, M. L. LoFaro, R. B. Uttamchandani, and L. D. Gelb. 1993. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann. Intern. Med. 118:321-330.
17. Spector, S. A., C. Kennedy, J. A. McCutchan, S. A. Bozzette, R. G. Straube, J. D. Connor, and D. D. Richman. 1989. The antiviral effect of zidovudine and rihavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J. Infect. Dis. 159:822-828.
18. U.S. Department of Health and Human Services. 1994. ACTG virology manual for HIV laboratories. Health Resources and Services Administration, Rockville, Md.